BusinessBioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten DiseaseBy Nasdaq OMXSep 15, 2016, 12:38 PM UTC
BusinessBioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual MeetingBy Nasdaq OMXSep 8, 2016, 8:30 AM UTC
BusinessBioMarin Announces Positive Data From Cerliponase Alfa Program for Treatment of CLN2 Disease, a Form of Batten Disease, at 12th Annual WORLDSymposium(TM) 2016By Nasdaq OMXMar 3, 2016, 12:05 AM UTC
BusinessBioMarin Announces 21 Presentations at 12th Annual WORLDSymposium™ 2016 February 29-March 4 in San Diego, California: 6 Oral and 15 PosterBy Nasdaq OMXFeb 29, 2016, 1:25 PM UTC
